San Diego-based Prometheus Laboratories, a developer of specialty pharmaceuticals, and the Regents of the University of California, Los Angeles campus, said Thursday night that they are in a exclusive research agreement. The two said that UCLA will focus on identification of biologal markers and mucosal healing in patients with Inflammatory Bowel Disease (IBD). Financial details of the research deal were not disclosed. Prometheus will fund the research activities at UCLA, which will be conducted in the lab of Dr. Jonathan Braun, at the UCLA David Geffen School of Medicine, and will hold a license to any technology developed in the lab.